AF
NPCE icon

Amalgamated Financial’s Neuropace NPCE Stock Holding History

Amalgamated Financial’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$9K Buy
+1,156
New +$9.97K ﹤0.01% 2913

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM

Amalgamated Financial's NPCE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Neuropace (NPCE) in Q1 2022: 1,156 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2913 among its holdings.

40 funds tracked by Wall St. Rank hold NPCE as of Q1 2022.

  • Amalgamated Financial held 1,156 shares of Neuropace worth $9K as of Q1 2022.
  • Neuropace was a new Amalgamated Financial position in Q1 2022.
  • Neuropace made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2913 holding.
  • 40 funds tracked by Wall St. Rank held Neuropace as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.